{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:38Z","timestamp":1788930518904,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00595-026-03331-y","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:37:02Z","timestamp":1781861822000},"page":"2378-2386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postoperative liver function trajectories and risk factors after hepatectomy for hepatocellular carcinoma"],"prefix":"10.1007","volume":"56","author":[{"given":"Masaki","family":"Omori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motochika","family":"Hamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Gon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Urade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Nanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"3","key":"3331_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"3331_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"3331_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1872-034X.2007.00216.x","volume":"38","author":"M Makuuchi","year":"2008","unstructured":"Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37\u201351.","journal-title":"Hepatol Res"},{"issue":"4","key":"3331_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"10126","key":"3331_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"20","key":"3331_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"10492","key":"3331_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851\u201364.","journal-title":"Lancet"},{"issue":"5","key":"3331_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2021","unstructured":"Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res. 2021;53(5):383\u201390.","journal-title":"Hepatol Res"},{"issue":"4","key":"3331_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00595-024-02930-x","volume":"55","author":"N Iseda","year":"2025","unstructured":"Iseda N, Itoh S, Toshima T, Yoshiya S, Bekki Y, Tsutsui Y, et al. Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study. Surg Today. 2025;55(4):510\u20137.","journal-title":"Surg Today"},{"issue":"6","key":"3331_CR10","first-page":"0","volume":"13","author":"K Akahoshi","year":"2024","unstructured":"Akahoshi K, Shindoh J, Tanabe M, Ariizumi S, Eguchi S, Okamura Y, et al. Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: the Japan liver cancer association and Japanese society of hepato-biliary-pancreatic surgery expert consensus statement 2023. Liver Cancer. 2024;13(6):0\u201310.","journal-title":"Liver Cancer."},{"issue":"7","key":"3331_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s00595-025-03009-x","volume":"55","author":"S Komatsu","year":"2025","unstructured":"Komatsu S, Yano Y, Terashima K, Fujishima Y, Ishida J, Ishihara N, et al. The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus. Surg Today. 2025;55(7):900\u20138.","journal-title":"Surg Today"},{"issue":"6","key":"3331_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/01.sla.0000189131.90876.9e","volume":"242","author":"S Balzan","year":"2005","unstructured":"Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. The \u201c50\u201350 criteria\u201d on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242(6):824\u20138.","journal-title":"Ann Surg"},{"issue":"9","key":"3331_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00595-025-03030-0","volume":"55","author":"T Ikehara","year":"2025","unstructured":"Ikehara T, Shimizu A, Kubota K, Notake T, Kitagawa N, Masuo H, et al. Appropriate methods of evaluating future liver remnant volume to predict postoperative liver failure after major hepatectomy based on the body mass of patients with normal hepatic reserve. Surg Today. 2025;55(9):1284\u201394.","journal-title":"Surg Today"},{"issue":"6","key":"3331_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3331_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/jgh.13250","volume":"31","author":"A Hiraoka","year":"2016","unstructured":"Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31(5):1031\u20136.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"3331_CR16","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s00268-019-05052-5","volume":"43","author":"S Komatsu","year":"2019","unstructured":"Komatsu S, Kido M, Tanaka M, Kuramitsu K, Tsugawa D, Awazu M, et al. Clinical relevance of reductive hepatectomy for Barcelona Clinic Liver Cancer stages B and C advanced hepatocellular carcinoma: a single-center experience of 102 patients. World J Surg. 2019;43(10):2571\u20138.","journal-title":"World J Surg"},{"issue":"4","key":"3331_CR17","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s11605-021-05181-0","volume":"26","author":"S Komatsu","year":"2022","unstructured":"Komatsu S, Kido M, Kuramitsu K, Tsugawa D, Gon H, Fukushima K, et al. Impact of hepatectomy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. J Gastrointest Surg. 2022;26(4):822\u201330.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"3331_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"3331_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","volume":"66","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338\u201346.","journal-title":"J Hepatol"},{"issue":"2","key":"3331_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/hbsn-23-122","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M. The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma. Hepatobil Surgery Nutrition. 2023;12(2):256\u201360.","journal-title":"Hepatobil Surgery Nutrition"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03331-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-026-03331-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-026-03331-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:36:17Z","timestamp":1788928577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-026-03331-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3331"],"URL":"https:\/\/doi.org\/10.1007\/s00595-026-03331-y","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval of the research protocol: This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review boards at all participating institutions. This multicenter cohort study was approved by the institutional review board of Kobe University Hospital, Hyogo, Japan (approval number B250180).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shohei Komatsu received honoraria and advisory fees from Chugai Pharmaceutical Co., Ltd. and AstraZeneca K.K. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}